Insulin Resistance Intervention after Stroke or TIA (IRIS)
Status: Open to Enrollment
Start Date: Sep 01 2005
End Date: OPEN
The IRIS trial is an international, multi-site investigation funded by the National Institute of Health (NIH).
The purpose of this study is to test the effectiveness of pioglitazone for preventing future strokes and heart attacks among persons with a recent ischemic stroke or transient ischemic attack (TIA). Pioglitazione is a medication that improves insulin resistance, a condition in which insulin, a normal human hormone, does not work effectively because the body is resistant to its effects. Insulin resistance can lead to diabetes and is thought to cause blood vessel disease, including stroke and heart attack, in patients with and without diabetes. Scientists believe that pioglitazone, by treating insulin resistance, may prevent stroke and heart attack. Recent clinical studies in diabetic patients have shown that patients who received pioglitazone had fewer heart attacks, strokes or deaths compared to patients treated with other medication (or an inactive pill). The IRIS trial will test if pioglitazone has similar benefits in non-diabetic patients with a recent stroke or TIA. The trial will also test the effectiveness of pioglitazone for preventing diabetes.
If you are 40 years of age or older and have had a stroke or TIA within the last 6 months you may be eligible for this trial.
- Inclusion Criteria:
- Age 40 or older
- Not diabetic
- Recent stroke or TIA (within past 6 months
Name: Suyi Niu, Research Coordinator
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician, we can help you find a University of Utah doctor or clinic location to meet your health care needs.
Although the studies described on this Web site may have potential benefits as described, the University of Utah and its physicians and affiliated hospitals cannot and do not guarantee or promise that you will receive any benefits from participating in a study.
The information posted on this site is consistent with the research reviewed and approved by the University of Utah Institutional Review Board (IRB). However, the IRB has not reviewed all material posted on this site. Contact the IRB if you have questions regarding your rights as a research participant. Also contact the IRB if you have questions, complaint, or concerns which you do not feel you can discuss with the investigator. The University of Utah IRB may be reached by phone at (801) 581-3655 or by e-mail at email@example.com.